BioSpace News Archive

Company shares exploded 373% at the news.

The two companies will combine their mRNA research to develop the potential vaccines across a range of infectious disease pathogens.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020.

No financial terms were disclosed, but they are apparently based on delivery time and dose volume.

Sanofi is lining up to spin off its active pharmaceutical ingredients division that will include a listing as a public company, Reuters reported, citing unnamed sources.

AstraZeneca’s COVID-19 vaccine candidate induced significant immune responses in the majority of patients following a single dose in a Phase I study. The preventative medication also proved to be fairly safe, study results showed.

Another COVID-19 vaccine candidate recently entered the races. The difference – this one is a live attenuated (weakened) virus expressing the coronavirus’s signature spike protein on its surface. And it’s delivered nasally, not a shot.

Thirty million doses expected to be delivered in 2020 and 2021, subject to regulatory approval or authorization

Molecular Partners AG announced that Allergan, an AbbVie company, has informed Molecular Partners of their intent to withdraw application filings with both the European Medicines Agency and the Japanese Regulatory Agency for abicipar pegol, a novel DARPin therapeutic for patients with neovascular age-related macular degeneration.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that the first patient has been dosed and continues on therapy in a trial assessing bemcentinib in recurrent glioblastoma.